Study Summary
The main purpose of this study is to evaluate the efficacy and safety of LY3857210 in participants with Osteoarthritic Pain
- Osteoarthritis, Knee
Treatment Effectiveness
Study Objectives
1 Primary · 13 Secondary · Reporting Duration: Baseline to Week 8
Trial Safety
Trial Design
2 Treatment Groups
LY3857210
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group
125 Total Participants · 2 Treatment Groups
Primary Treatment: LY3857210 · Has Placebo Group · Phase 2
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:About The Reviewer
Michael Gill - B. Sc.
First Published: October 22nd, 2021
Last Reviewed: November 19th, 2022
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.